Carolina Selman Bravo

Carolina Selman Bravo

Auto-generated profile, based on publicly available information

Carolina Selman Bravo

Diagnostic Units, Arturo Lopez Perez Foundation, Santiago, Chile

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Genes
Verified
Journal Article
Open access
PDF file
ISIskra Signore
Iskra Signore
GDGerardo Donoso
Gerardo Donoso
PBPamela Bocchieri
Pamela Bocchieri
ETEduardo Tobar-Calfucoy
Eduardo Tobar-Calfucoy
CYCristian Yáñez
Cristian Yáñez
ACAlicia Colombo
Alicia Colombo
Although a lack of diversity in genetic studies is an acknowledged obstacle for personalized medicine and precision public health, Latin American populations remain particularly understudied despite their heterogeneity and mixed ancestry. This gap extends to COVID-19 despite its variability in susceptibility and clinical course, where ethnic background appears to influence disease severity, with non-Europeans facing higher hospitalization rates. In addition, access to high-quality samples and data is a critical issue for personalized and precision medicine, and it has become clear that the solution lies in biobanks. The creation of the Chilean COVID-19 Biorepository reported here addresses these gaps, representing the first nationwide multicentric Chilean initiative. It operates under rigorous biobanking standards and serves as one of South America’s largest COVID cohorts. A centralized harmonization strategy was chosen and included unified standard operating procedures, a sampling coding system, and biobanking staff training. Adults with confirmed SARS-CoV-2 infection provided broad informed consent. Samples were collected to preserve blood, plasma, buffy coat, and DNA. Quality controls included adherence to the standard preanalytical code, incident reporting, and DNA concentration and absorbance ratio 260/280 assessments. Detailed sociodemographic, health, medication, and preexisting condition data were gathered. In five months, 2262 participants were enrolled, pseudonymized, and sorted by disease severity. The average Amerindian ancestry considering all participant was 44.0% [SD 15.5%], and this value increased to 61.2% [SD 19.5%] among those who self-identified as Native South Americans. Notably, 279 participants self-identified with one of 12 ethnic groups. High compliance (>90%) in all assessed quality controls was achieved. Looking ahead, our team founded the COVID-19 Genomics Network (C19-GenoNet) focused on identifying genetic factors influencing SARS-CoV-2 outcomes. In conclusion, this bottom-up collaborative effort aims to promote the integration of Latin American populations into global genetic research and welcomes collaborations supporting this endeavor. Interested parties are invited to explore collaboration opportunities through our catalog, accessible online.

Verified
Journal Article
Open access
PDF file
FVFranz Villarroel-Espíndola
Franz Villarroel-Espíndola
LJLeyla Lumturi Jaupi
Leyla Lumturi Jaupi
JRJoaquin Reyes
Joaquin Reyes
CBCarlos Barrientos
Carlos Barrientos
CPCelia Podestá
Celia Podestá
PBPía Bascur
Pía Bascur
The histological changes in the gastric epithelium are crucial in the progression from premalignant to neoplastic lesions. TLR4, TLR5 and TLR9 have been localized in the gastric epithelium and studied separately using conventional histological techniques without a focus on the protein or cell interactions within the microenvironment. Therefore, we developed a multiplex immunohistochemistry/immunofluorescence (mIHC/IF) technology for the simultaneous detection of TLR4, TLR5 and TLR9 on a single tissue section of human gastric biopsies from 10 paired cases collected in two independent visits, and its correlation with the OLGA/OLGIM scoring and H. pylori status after eradication. The results confirmed that mIHC/IF is useful for simultaneously interrogating six biomarkers and demonstrated that TLR4 and TLR9 are significantly associated with H. pylori infection. However, only TLR9 is positively related to the presence of intestinal metaplasia. TLR5 was mainly present in goblet cells (TFF3+) but did not show any significant association with H. pylori or the presence of intestinal metaplasia. Our results suggest that a more comprehensive strategy to interrogate the tissue microenvironment in premalignant lesions may improve the interpretation of the earned risk of gastric cancer in patients with chronic gastritis and evidence of failure in H. pylori eradication.

2 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RGRaimundo Gazitúa
Raimundo Gazitúa
JBJosé Luis Briones
José Luis Briones
CSCarolina Selman
Carolina Selman
FVFranz Villarroel-Espíndola
Franz Villarroel-Espíndola
AAAdam Aguirre
Adam Aguirre
CCChristian Caglevic
Christian Caglevic
Background The use of convalescent plasma (CP) to treat COVID-19 has shown promising results; however, its effectiveness remains uncertain. The purpose of this study was to determine the safety and mortality of CP among patients hospitalized with COVID-19. Study Design and Methods This multicenter, open-label, uncontrolled clinical trial is currently being conducted at nine hospitals in Chile. Patients hospitalized due to COVID-19 who were still within 14 days since symptom onset were classified into four groups: Patients with cancer and severe COVID-19. Patients with cancer and non-severe COVID-19. Patients with severe COVID-19 and patients with non-severe COVID-19 only. The intervention involved two 200-cc. CP transfusions with anti-SARS-CoV-2 IgG titers ≥ 1:320 collected from COVID-19-recovered donors. Results 192 patients hospitalized for COVID-19 received CP transfusions. At the first transfusion, 90.6% fulfilled the criteria for severity, and 41.1% required mechanical ventilation. 11.5% of the patients had cancer. Overall 7-day and 30-day mortality since the first CP transfusion was 5.7% and 16.1% respectively. There were no differences at either time point in mortality between the four groups. Patients on mechanical ventilation when receiving CP had higher mortality rates than those who were not (22.8% vs. 11.5%; p = 0.037). Overall 30-day mortality was higher in patients over 65 than in younger patients (p = 0.019). Severe adverse events were reported in four patients (2.1%) with an overall transfusion-related lung injury rate of 1.56%. No CP-related deaths occurred. Discussion CP is safe when used in patients with COVID-19 even when also presenting severity criteria or risk factors. Our mortality rate is comparable to reports from larger studies. Controlled clinical trials are required to determine efficacy. Registration NCT04384588

7 May 2026 in Andes Pediatrica
Verified
Journal Article
Open access
PDF file
RFRicardo Ubilla Fuentes
Ricardo Ubilla Fuentes
VFVíctor Faundes
Víctor Faundes
FMFernanda Martin Merlez
Fernanda Martin Merlez
SMSonia Beatriz Margarit
Sonia Beatriz Margarit
MLMarcela Lagos Lucero
Marcela Lagos Lucero
MHMarcela Schulz Haramoto
Marcela Schulz Haramoto
El uso clínico de estudios genético-moleculares ha aumentado significativamente y existe acuerdo sobre la necesidad de informes claros, estructurados y clínicamente interpretables. Este documento representa un consenso intersocietario que establece recomendaciones sobre el diseño y reporte de estudios genético-moleculares en el contexto clínico. Su elaboración consideró la revisión de guías internacionales vigentes, así como su adaptación a la normativa y práctica nacional. El consenso fue desarrollado entre junio y diciembre de 2025 mediante un trabajo colaborativo entre la Rama de Genética de la Sociedad Chilena de Pediatría (SOCHIPE), la Sociedad de Genética de Chile (SOCHIGEN), la Sociedad Chilena de Asesoramiento Genético en Oncología (SOCHIAGO), la Sociedad Médica de Laboratorio Clínico (SMLC) y la Sociedad Chilena de Anatomía Patológica (SCHAP), con la colaboración técnica de representantes del Instituto de Salud Pública (ISP). Se realizaron reuniones periódicas y revisión iterativa de los contenidos. Se definieron los elementos esenciales que deben incluir los informes de estudios genéticos, tales como información administrativa y clínica, metodología, limitaciones, reporte de variantes, interpretación de resultados e implicancias clínicas. Asimismo, la recomendación de realización de asesoramiento genético y del proceso de consentimiento informado previo a la toma de exámenes genéticos. El objetivo de este documento es servir como referencia para laboratorios y profesionales de la salud, promoviendo la elaboración de informes claros, estructurados y clínicamente útiles. Se espera que su implementación contribuya a mejorar la calidad, homogeneidad e interpretación de los estudios genéticos, favoreciendo la toma de decisiones clínicas y la equidad en el acceso a diagnóstico.

14 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
YEYolanda Espinosa-Parrilla
Yolanda Espinosa-Parrilla
MFMacarena Fuentes-Guajardo
Macarena Fuentes-Guajardo
LCLaura Carvajal-Silva
Laura Carvajal-Silva
KAKevin Aguilar-Valdés
Kevin Aguilar-Valdés
ISIskra Signore
Iskra Signore
RVRicardo Verdugo
Ricardo Verdugo
Background: More than five years after the COVID-19 outbreak, the infection by the SARS-CoV-2 virus should still be considered as a global threat with highly heterogeneous clinical outcomes from asymptomatic to fatal depending on existing genetic and phenotypic inter-individual and inter-population variability. Our objective is to identify risk loci associated with COVID-19 in an admixed Latin American population. Methods: We performed a genome-wide association study in the framework of the Chilean C19-GenoNet team, analyzing a cohort of 3,417 individuals recruited from the northernmost to the southernmost regions of the country, who presented variations in the severity of their COVID-19 clinical manifestations. Results: Our investigation replicated the extensively reported association of several variants at the 3p21.31 locus with COVID-19 severity and found a suggestive association for a variant within the FOXP4 gene at 6p21.1 with COVID-19 hospitalization. Both associations appear to be shared with other populations. Importantly, our study identified three previously unreported loci associated with COVID-19 severity or hospitalization at 7q21.11, 16p13.12 and 6p25.3, and one additional locus at 4p13 associated with SARS-CoV-2 positivity, a proxy for infection susceptibility. Conclusions: these new risk loci may represent population-specific effects in Chilean and, potentially, other Latin American admixed groups. Our study highlights the importance of expanding efforts to study underrepresented and genetically different populations, which may provide new clues on the genetic basis of human diseases and may help to anticipate global responses to emerging viral infections and future pandemics.

29 January 2026 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
ASAndrés Soto
Andrés Soto
JTJavier Tinoco-Cahuana
Javier Tinoco-Cahuana
PCPaulo Charpentier-Videla
Paulo Charpentier-Videla
EREdgardo Rojas-Mancilla
Edgardo Rojas-Mancilla
DMDiego Macias-Cofre
Diego Macias-Cofre
FSFrancisca Sanchez-Jorquera
Francisca Sanchez-Jorquera
Candida inconspicua is an uncommon opportunistic yeast, increasingly reported in immunocompromised patients. We describe a case of asymptomatic Candiduria caused by C. inconspicua in a 43‐year‐old woman with Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukemia undergoing chemotherapy. During multiple episodes of high‐risk febrile neutropenia, urine cultures repeatedly isolated C. inconspicua , identified via MALDI‐TOF MS and exhibiting high fluconazole resistance (MIC: 16.0 μg/mL). Despite these findings, no antifungal therapy was administered due to the absence of urinary symptoms and resolution of fever with antibacterial treatment. This case illustrates the clinical dilemma posed by rare, drug‐resistant Candida species in asymptomatic infections, emphasizing the importance of precise microbiological identification and antimicrobial stewardship. The emergence of C. inconspicua , with potential for resistance and biofilm formation, underscores the need for careful evaluation in hemato‐oncological patients, particularly when considering the risks and benefits of initiating antifungal therapy in the absence of clinical symptoms.